Imbruvica

Chemical Nameibrutinib
Dosage FormCapsules (oral; 70mg and 140mg); Tablet (oral; 140mg, 280mg, 420mg, and 560mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyPharmacyclics LLC
Approval Year2013

Indication

  • For the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
  • For the treatment of chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) in adult patients.
  • For the treatment of chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion in adult patients.
  • For the treatment of waldenström’s macroglobulinemia (WM) in adult patients.
  • For the treatment of marginal zone lymphoma (MZL) in adult patients who require systemic therapy and have received at least one prior anti-CD20-based therapy.
  • For the treatment of chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Last updated on 6/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Imbruvica (ibrutinib) Prescribing Information2013Pharmacyclics LLC, Sunnyvale CA